These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

150 related items for PubMed ID: 33308111

  • 1. Histone Deacetylase Inhibitors and Papillary Thyroid Cancer.
    Spartalis E, Kotrotsios K, Chrysikos D, Spartalis M, Paschou SA, Schizas D, Tsamakis K, Dimitroulis D, Troupis T, Nikiteas N.
    Curr Pharm Des; 2021; 27(18):2199-2208. PubMed ID: 33308111
    [Abstract] [Full Text] [Related]

  • 2. Histone Deacetylase Inhibitors and Anaplastic Thyroid Carcinoma.
    Spartalis E, Athanasiadis DI, Chrysikos D, Spartalis M, Boutzios G, Schizas D, Garmpis N, Damaskos C, Paschou SA, Ioannidis A, Tsourouflis G, Dimitroulis D, Nikiteas NI.
    Anticancer Res; 2019 Mar; 39(3):1119-1127. PubMed ID: 30842140
    [Abstract] [Full Text] [Related]

  • 3. Potential anti-cancer effect of N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA), a novel histone deacetylase inhibitor, for the treatment of thyroid cancer.
    Kim SM, Park KC, Jeon JY, Kim BW, Kim HK, Chang HJ, Choi SH, Park CS, Chang HS.
    BMC Cancer; 2015 Dec 23; 15():1003. PubMed ID: 26698299
    [Abstract] [Full Text] [Related]

  • 4. Belinostat and panobinostat (HDACI): in vitro and in vivo studies in thyroid cancer.
    Chan D, Zheng Y, Tyner JW, Chng WJ, Chien WW, Gery S, Leong G, Braunstein GD, Koeffler HP.
    J Cancer Res Clin Oncol; 2013 Sep 23; 139(9):1507-14. PubMed ID: 23824064
    [Abstract] [Full Text] [Related]

  • 5. Histone Deacetylase Inhibitors: A Novel Therapeutic Weapon Against Medullary Thyroid Cancer?
    Damaskos C, Garmpis N, Valsami S, Spartalis E, Antoniou EA, Tomos P, Karamaroudis S, Zoumpou T, Pergialiotis V, Stergios K, Michaelides C, Kontzoglou K, Perrea D, Nikiteas N, Dimitroulis D.
    Anticancer Res; 2016 Oct 23; 36(10):5019-5024. PubMed ID: 27798860
    [Abstract] [Full Text] [Related]

  • 6. Histone Deacetylase Inhibitors Dose-Dependently Switch Neutrophil Death from NETosis to Apoptosis.
    Hamam HJ, Palaniyar N.
    Biomolecules; 2019 May 11; 9(5):. PubMed ID: 31083537
    [Abstract] [Full Text] [Related]

  • 7. Recent Progress in Histone Deacetylase Inhibitors as Anticancer Agents.
    Cappellacci L, Perinelli DR, Maggi F, Grifantini M, Petrelli R.
    Curr Med Chem; 2020 May 11; 27(15):2449-2493. PubMed ID: 30332940
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells.
    Takai N, Desmond JC, Kumagai T, Gui D, Said JW, Whittaker S, Miyakawa I, Koeffler HP.
    Clin Cancer Res; 2004 Feb 01; 10(3):1141-9. PubMed ID: 14871994
    [Abstract] [Full Text] [Related]

  • 10. Pharmacogenomics and histone deacetylase inhibitors.
    Goey AK, Sissung TM, Peer CJ, Figg WD.
    Pharmacogenomics; 2016 Nov 01; 17(16):1807-1815. PubMed ID: 27767376
    [Abstract] [Full Text] [Related]

  • 11. Downregulation of Nrf2 by the combination of TRAIL and Valproic acid induces apoptotic cell death of TRAIL-resistant papillary thyroid cancer cells via suppression of Bcl-xL.
    Cha HY, Lee BS, Chang JW, Park JK, Han JH, Kim YS, Shin YS, Byeon HK, Kim CH.
    Cancer Lett; 2016 Mar 01; 372(1):65-74. PubMed ID: 26721202
    [Abstract] [Full Text] [Related]

  • 12. Modulation of matrix metalloproteinase activity in human thyroid cancer cell lines using demethylating agents and histone deacetylase inhibitors.
    Mitmaker EJ, Griff NJ, Grogan RH, Sarkar R, Kebebew E, Duh QY, Clark OH, Shen WT.
    Surgery; 2011 Apr 01; 149(4):504-11. PubMed ID: 21193210
    [Abstract] [Full Text] [Related]

  • 13. Histone deacetylase inhibitors are potent inducers of gene expression in latent EBV and sensitize lymphoma cells to nucleoside antiviral agents.
    Ghosh SK, Perrine SP, Williams RM, Faller DV.
    Blood; 2012 Jan 26; 119(4):1008-17. PubMed ID: 22160379
    [Abstract] [Full Text] [Related]

  • 14. Notch1 mediates growth suppression of papillary and follicular thyroid cancer cells by histone deacetylase inhibitors.
    Xiao X, Ning L, Chen H.
    Mol Cancer Ther; 2009 Feb 26; 8(2):350-6. PubMed ID: 19190121
    [Abstract] [Full Text] [Related]

  • 15. Panobinostat, a pan-histone deacetylase inhibitor: rationale for and application to treatment of multiple myeloma.
    Cheng T, Grasse L, Shah J, Chandra J.
    Drugs Today (Barc); 2015 Aug 26; 51(8):491-504. PubMed ID: 26380387
    [Abstract] [Full Text] [Related]

  • 16. Inhibition of class IIa histone deacetylase activity by gallic acid, sulforaphane, TMP269, and panobinostat.
    Choi SY, Kee HJ, Jin L, Ryu Y, Sun S, Kim GR, Jeong MH.
    Biomed Pharmacother; 2018 May 26; 101():145-154. PubMed ID: 29482060
    [Abstract] [Full Text] [Related]

  • 17. HTP Nutraceutical Screening for Histone Deacetylase Inhibitors and Effects of HDACis on Tumor-suppressing miRNAs by Trichostatin A and Grapeseed (Vitis vinifera) in HeLa cells.
    Mazzio EA, Soliman KF.
    Cancer Genomics Proteomics; 2017 Jan 02; 14(1):17-33. PubMed ID: 28031235
    [Abstract] [Full Text] [Related]

  • 18. Inhibitors of histone deacetylase as antitumor agents: A critical review.
    Manal M, Chandrasekar MJ, Gomathi Priya J, Nanjan MJ.
    Bioorg Chem; 2016 Aug 02; 67():18-42. PubMed ID: 27239721
    [Abstract] [Full Text] [Related]

  • 19. Romidepsin (FK228), A Histone Deacetylase Inhibitor and its Analogues in Cancer Chemotherapy.
    Pojani E, Barlocco D.
    Curr Med Chem; 2021 Aug 02; 28(7):1290-1303. PubMed ID: 32013816
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.